📊 INGN Key Takeaways
Is Inogen Inc (INGN) a Good Investment?
Inogen demonstrates strong top-line growth (+18.1% YoY) and maintains fortress-like balance sheet strength with $93.1M cash and negligible debt, but operationally deteriorates with negative operating income (-$9.3M), negative operating cash flow (-$6.7M), and negative free cash flow despite revenue expansion. The fundamental disconnect between 18% revenue growth and persistent unprofitability indicates operational leverage challenges or structural margin pressures that create unacceptable risk without clear evidence of profitability trajectory.
Inogen shows credible top-line momentum, with revenue up 18.1% year over year, and its balance sheet is a clear strength given over $103M of cash, minimal long-term debt, and strong liquidity ratios. However, the business is still unprofitable at both the operating and net income levels, and cash generation remains negative, so the core question is whether recent growth can convert into durable margin improvement. Fundamentally, this looks like a financially stable turnaround story rather than a high-quality profit compounder today.
Why Buy Inogen Inc Stock? INGN Key Strengths
- Strong revenue growth of 18.1% YoY demonstrates sustained market demand
- Excellent liquidity position with $93.1M cash and 3.1x current ratio provides operational flexibility
- Debt-free balance sheet ($80K long-term debt) with strong equity base ($182.9M) minimizes financial distress risk
- Improving loss trend with EPS improving 43.4% YoY suggests margin trajectory is turning
- Healthy gross margin of 44.5% indicates reasonable unit economics and pricing power
- Revenue growth is strong at 18.1% year over year, indicating improving demand or sales execution
- Balance sheet is conservatively structured with high cash reserves, negligible long-term debt, and solid liquidity
- Losses are narrowing, with net income and diluted EPS improving meaningfully year over year
INGN Stock Risks: Inogen Inc Investment Risks
- Operating unprofitability with -$9.3M operating income and -$8.3M net income despite revenue growth signals operational dysfunction
- Negative operating cash flow of -$6.7M reveals core business is cash-consumptive, requiring balance sheet depletion to fund operations
- Negative return on equity (-4.6%) and assets (-2.9%) shows inefficient capital deployment and value destruction for shareholders
- Operating margin of -11% suggests fixed cost base is not absorbing into scaling revenue model as expected
- Cash burn trajectory is unsustainable if profitability improvement does not materialize within 1-2 years
- Operating margin remains negative at -8.7%, showing the business model has not yet reached sustainable profitability
- Operating cash flow and free cash flow are still negative, which weakens the quality of earnings improvement
- Returns on equity and assets remain negative, indicating capital is not yet being deployed at attractive economic returns
Key Metrics to Watch
- Operating cash flow inflection - must turn positive within next 2 quarters to validate turnaround
- Operating margin improvement - track path to 5%+ operating margin as revenue continues scaling
- Cash burn rate - monitor quarterly cash consumption to estimate runway if profitability delays
- Gross margin stability - ensure 44.5% margin is defended as company scales
- SG&A expense ratio - identify whether cost structure can scale with 18%+ revenue growth
- Operating margin progression toward sustained positive territory
- Operating cash flow and free cash flow conversion as revenue grows
Inogen Inc (INGN) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 3.10x current ratio provides a solid financial cushion.
INGN Profit Margin, ROE & Profitability Analysis
INGN vs Healthcare Sector: How Inogen Inc Compares
How Inogen Inc compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Inogen Inc Stock Overvalued? INGN Valuation Analysis 2026
Based on fundamental analysis, Inogen Inc has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Inogen Inc Balance Sheet: INGN Debt, Cash & Liquidity
INGN Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Inogen Inc's revenue has declined by 13% over the 5-year period, indicating business contraction. The most recent EPS of $-4.42 indicates the company is currently unprofitable.
INGN Revenue Growth, EPS Growth & YoY Performance
INGN Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $68.5M | -$6.2M | $-0.25 |
| Q3 2025 | $74.9M | -$5.3M | $-0.20 |
| Q2 2025 | $74.4M | -$4.2M | $-0.15 |
| Q1 2025 | $63.1M | -$6.2M | $-0.25 |
| Q3 2024 | $68.0M | -$6.0M | $-0.25 |
| Q2 2024 | $68.3M | -$5.6M | $-0.24 |
| Q1 2024 | $55.9M | -$14.6M | $-0.62 |
| Q3 2023 | $68.0M | -$9.5M | $-0.42 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Inogen Inc Dividends, Buybacks & Capital Allocation
INGN SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Inogen Inc (CIK: 0001294133)
📋 Recent SEC Filings
❓ Frequently Asked Questions about INGN
What is the AI rating for INGN?
Inogen Inc (INGN) has a Combined AI Rating of SELL from Claude (SELL) and ChatGPT (HOLD) with 76% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are INGN's key strengths?
Claude: Strong revenue growth of 18.1% YoY demonstrates sustained market demand. Excellent liquidity position with $93.1M cash and 3.1x current ratio provides operational flexibility. ChatGPT: Revenue growth is strong at 18.1% year over year, indicating improving demand or sales execution. Balance sheet is conservatively structured with high cash reserves, negligible long-term debt, and solid liquidity.
What are the risks of investing in INGN?
Claude: Operating unprofitability with -$9.3M operating income and -$8.3M net income despite revenue growth signals operational dysfunction. Negative operating cash flow of -$6.7M reveals core business is cash-consumptive, requiring balance sheet depletion to fund operations. ChatGPT: Operating margin remains negative at -8.7%, showing the business model has not yet reached sustainable profitability. Operating cash flow and free cash flow are still negative, which weakens the quality of earnings improvement.
What is INGN's revenue and growth?
Inogen Inc reported revenue of $85.1M.
Does INGN pay dividends?
Inogen Inc does not currently pay dividends.
Where can I find INGN SEC filings?
Official SEC filings for Inogen Inc (CIK: 0001294133) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is INGN's EPS?
Inogen Inc has a diluted EPS of $-0.30.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is INGN a good stock to buy right now?
Based on our AI fundamental analysis in May 2026, Inogen Inc has a SELL rating with 76% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is INGN stock overvalued or undervalued?
Valuation metrics for INGN: ROE of -4.6% (sector avg: 15%), net margin of -9.8% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy INGN stock in 2026?
Our dual AI analysis gives Inogen Inc a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is INGN's free cash flow?
Inogen Inc's operating cash flow is $-6.7M, with capital expenditures of $210.0K. FCF margin is -8.1%.
How does INGN compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -9.8% (avg: 12%), ROE -4.6% (avg: 15%), current ratio 3.10 (avg: 2).